President Biden recently signed a bill into law that eases federal restrictions on marijuana research.
The Medical Marijuana and Cannabidiol (CBD) Research Expansion Act establishes a new, separate registration process to facilitate research on marijuana. The Act directs the Drug Enforcement Administration (DEA) to follow specific procedures to register:
The Act allows certain registered entities (institutes of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or CBD for the purpose of medical research.
The Act includes other provisions including those that:
Why is the Act significant?
The Act lessens federal restrictions on marijuana, which is still a Schedule 1 controlled substance, by making it easier for researchers to petition for and utilize large amounts of marijuana. In addition, the Act simplifies the application process for the approval of scientific marijuana-related studies, making it easier for researchers to understand the potential benefits and drawbacks of cannabis and CBD.
Help is available
The attorneys at O’Reilly Rancilio are available to answer questions about laws related to medical and recreational marijuana. To learn more, please visit our website or call 586-726-1000.
© 2024 O'Reilly Rancilio P.C.|Legal Disclaimer|Privacy Policy